What Researchers Did
Researchers reviewed the clinical and economic potential of hyperbaric oxygen therapy (HBOT) for conditions like diabetic ulceration, discussing the situation in the United Kingdom and available evidence.
What They Found
The review indicated increasing evidence that hyperbaric oxygen therapy (HBOT) could offer clinical efficacy and cost-efficiency for conditions like nonhealing diabetic ulceration. Chronic wound care in the UK is estimated to cost over £1 billion annually, with diabetic ulceration accounting for a substantial portion, yet there is insufficient high-quality evidence to properly assess HBOT's contribution.
What This Means for Canadian Patients
Canadian patients with nonhealing diabetic ulceration might potentially benefit from hyperbaric oxygen therapy (HBOT) as a treatment option. However, robust clinical trials are still needed to definitively establish its effectiveness and cost-efficiency in a Canadian healthcare context.
Canadian Relevance
This review primarily discusses the situation and costs within the United Kingdom, and therefore has no direct Canadian connection.
Study Limitations
A significant limitation highlighted by the review is the insufficient good-quality evidence from randomized controlled trials to make properly informed decisions about hyperbaric oxygen therapy.